IAI. Ahmad

I. Ahmad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


I. Ahmad has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • E. Kostantin

    Biochemistry, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada

    1 shared publication
  • G. J. Tsongalis

    Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

    1 shared publication
  • J. Roy

    Haematology and Medical Oncology, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada

    1 shared publication
  • M. Guimond

    Department of Microbiology, Infectious Diseases & Immunology, Université de Montréal, Montreal, QC, Canada

    1 shared publication
  • M. Newmarch

    Haematology and Medical Oncology, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada

    1 shared publication
  • Vincent De Guire

    Clinical Biochemistry Department and Research Center of Maisonneuve-Rosemont Hospital , Department of Biochemistry and Molecular Medicine of the Université de Montréal , Montreal , QC , Canada

    1 shared publication

Latest Publications

  • MicroRNAs in graft-versus-host disease: a review of the latest data

    by M. Newmarch, E. Kostantin, G. J. Tsongalis, M. Guimond, J. Roy, V. De Guire, I. Ahmad

    Detectable in biopsies and body fluids, the measurement of a single or panels of microRNAs have been reported to be quite sensitive and specific for the prediction, diagnosis, and prognosis of many diseases. Interest in the use of microRNAs as biomarkers and eventual therapeutic targets has increased exponentially in the last decade. However, in the field of graft-versus-host disease (GVHD), the discovery of their involvement in biological processes and their predictive value is only emerging. With 30–75% of patients developing GVHD following allogeneic hematopoietic cell transplant and the absence of routinely used predictive biomarkers, microRNAs are promising for early detection and follow-up of this condition. We aim to summarize the current knowledge on the involvement of these small RNAs in the pathophysiology of this disease. We also review studies investigating the potential of miRNAs as biomarkers for early detection, follow-up, and prognosis of GVHD.